Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated vs Conventional CCRT in Esophageal SCC
NCT06912074Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival Rate at 2 years. Started Apr 2025; status: recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06912074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912074.